GLP-1 drugsIn silico

Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes

Figure 1 from International Journal of Obesity — Figure 1Ciudin et al.

International Journal of Obesity

The paper

Andreea Ciudin, Erin Johansson, Sarah Zimner-Rapuch,

Georgios K. Dimitriadis, Marine Bertrand, Tristan Curteis, Laura J. Clark, Ludi Fan, Hélène Sapin,

Jean-Francois Bergmann

Hebron University · Université Paris Cité

International Journal of Obesity · 28 Sep 2026

doi.org/10.1038/s41366-026-02229-6 PubMed 42806056

GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD
Diabetes, Obesity & Metabolism · 4 Oct 2026
Six blood metabolites distinguish metabolic health in obesity
Frontiers in Endocrinology · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026